<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02227927</url>
  </required_header>
  <id_info>
    <org_study_id>CCF-Domperidone</org_study_id>
    <secondary_id>CCF-Domperidone</secondary_id>
    <nct_id>NCT02227927</nct_id>
  </id_info>
  <brief_title>Treatment Use of Domperidone for Gastroparesis</brief_title>
  <official_title>Treatment Use of Domperidone for Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scott Gabbard, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <brief_summary>
    <textblock>
      Domperidone is a drug that may be of benefit to individuals with gastroesophageal reflux&#xD;
      disease (GERD), with upper GI symptoms, gastroparesis, and chronic constipation.&#xD;
&#xD;
      This is a long-term treatment program for prescription of this drug to all patients who, in&#xD;
      the investigators' judgement, could benefit from its use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Treatment Use of Domperidone program is also available at the Cleveland Clinic&#xD;
      Florida/Weston Gastroenterology Department. This is not a &quot;traditional&quot; research study, but&#xD;
      an expanded use protocol for patients who may benefit from the drug. Because of this, this&#xD;
      study is enrolling patients via invitation only, and as such, all expenses associated with&#xD;
      the drug, initiation and follow up of treatment are the responsibility of the patient or the&#xD;
      patient's third party payer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Gastroesophageal Reflux Disease</condition>
  <condition>GERD</condition>
  <condition>Gastroparesis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>10-30mg oral dose, four times daily.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age 18 and older&#xD;
&#xD;
          -  Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn,&#xD;
             upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility&#xD;
             disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation&#xD;
             that are refractory to standard therapy.&#xD;
&#xD;
          -  Patients must have a comprehensive evaluation to eliminate other causes of their&#xD;
             symptoms.&#xD;
&#xD;
          -  Patient has signed informed consent for the administration of domperidone that informs&#xD;
             the patient of potential adverse events including:&#xD;
&#xD;
               -  increased prolactin levels&#xD;
&#xD;
               -  extrapyramidal side effects&#xD;
&#xD;
               -  breast changes&#xD;
&#xD;
               -  cardiac arrhythmias including QT prolongation and death&#xD;
&#xD;
               -  There is a potential for increased risk of adverse events with the drugs listed&#xD;
                  in the domperidone protocol addendum.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of, or current, arrhythmias including ventricular tachycardia, ventricular&#xD;
             fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are&#xD;
             not necessarily excluded.&#xD;
&#xD;
          -  Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged&#xD;
             QTc (QTc&gt; 450 milliseconds for males, QTc&gt;470 milliseconds for females).&#xD;
&#xD;
          -  Clinically significant electrolyte disorders.&#xD;
&#xD;
          -  Gastrointestinal hemorrhage or obstruction&#xD;
&#xD;
          -  Presence of a prolactinoma (prolactin-releasing pituitary tumor).&#xD;
&#xD;
          -  Pregnant or breast feeding female&#xD;
&#xD;
          -  Known allergy to domperidone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ellari Hodges</last_name>
    <phone>216 442-6652</phone>
    <email>HODGESE@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Matyas</last_name>
    <phone>216 445-3455</phone>
    <email>MATYASC@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Alison Schneider, MD</last_name>
      <phone>954-659-5646</phone>
      <email>schneia2@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Scott Gabbard, MD</last_name>
      <phone>216-444-6523</phone>
      <email>GABBARS@ccf.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 25, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2014</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Scott Gabbard, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Gastroesophageal Reflux Disease</keyword>
  <keyword>GERD</keyword>
  <keyword>Gastroparesis</keyword>
  <keyword>Domperidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

